{
    "clinical_study": {
        "@rank": "30227", 
        "arm_group": {
            "arm_group_label": "Not applicable-observational study", 
            "description": "Not applicable-observational study"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study was to assess the incidence rate of the major adverse\n      cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin\n      therapy in patients who have history of acute myocardial infarction and are diagnosed with\n      metabolic syndrome."
        }, 
        "brief_title": "Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)", 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myocardial Infarction", 
                "Metabolic Syndrome X"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients >20 years of age.\n\n          -  history of acute myocardial infarction\n\n          -  metabolic syndrome diagnosis\n\n        Exclusion Criteria:\n\n          -  current liver disease or AST or ALT greater than 3 times the upper limit of reference\n             range\n\n          -  pre-existing gallbladder disease\n\n          -  moderate to severe renal disorder (serum creatinine >2.5mg/dL)\n\n          -  pancreatitis diagnosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects aged more than 20 with history of acute myocardial infarction and diagnosed with\n        metabolic syndrome"
            }
        }, 
        "enrollment": {
            "#text": "1573", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069717", 
            "org_study_id": "DW_FAMI_001"
        }, 
        "intervention": {
            "arm_group_label": "Not applicable-observational study", 
            "intervention_name": "Not applicable-observational study", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Fenofibrate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "contact": {
                "email": "shj@daewoong.co.kr", 
                "last_name": "Myung Ho Jeong, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Gwangju", 
                    "country": "Korea, Republic of", 
                    "zip": "501-757"
                }, 
                "name": "Chonnam national university hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "cardiac death, MI, re-PCI, CABG", 
            "measure": "The incidence rate of the major adverse cardiovascular events (MACE)", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "non-cardiac death, stroke, hospitalization for acute coronary syndrome", 
            "measure": "The incidence rate of the major adverse cardiac and cerebrovascular event (MACCE)", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "source": "Daewoong Pharmaceutical Co. LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "24 Months", 
        "verification_date": "February 2014"
    }
}